Erschienen in:
01.02.2021 | ASO Author Reflections
ASO Author’s Reflections: Are Genomic Assays Informing the Management of Ductal Carcinoma in situ as They Have for Invasive Breast Cancer?
verfasst von:
Mara A. Piltin, DO, Judy C. Boughey, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 8/2021
Einloggen, um Zugang zu erhalten
Excerpt
The ultimate goal in managing ductal carcinoma in situ (DCIS) is to prevent recurrence or invasion into surrounding breast stroma, because DCIS is an extremely survivable form of early breast cancer.
1,
2 In some centers, DCIS is no longer even considered breast cancer and is considered a precursor lesion, as studies continue to discover more about the way it behaves as a disease process. Genomic assays developed to analyze the individual behavior of invasive tumors have been incorporated into both national guidelines and standard management protocols for invasive breast cancer to guide the use of systemic therapy.
3 Similar genomic prognostic assays have been developed to aid in the analysis of DCIS, but reports on how they are influencing adjuvant therapy decisions have been limited.
4,
5 …